Recent Trial Data: CRISPR Therapeutics (CRSP) has sparked significant discussion on X following the release of promising Phase 1 data for CTX310, a gene-editing therapy targeting ANGPTL3. Posts highlight impressive reductions in triglycerides and LDL cholesterol, with some calling it a potential game-changer. The buzz centers on the therapy’s safety profile and upcoming Phase 1b plans.
Market Reactions: Despite the positive clinical news, X discussions note a recent drop in CRSP stock price, with a close at $55.16 reflecting a 2.56% decline. Some users express frustration over the stock’s volatility, while others remain optimistic about long-term growth tied to therapies like Casgevy. Analyst sentiments, including a lowered price target from Wedbush, are also circulating.
Future Potential: Conversations on X also touch on the broader implications of CRISPR technology, with users debating the impact of potential FDA guidance on gene-editing approvals. Many see CRSP as a leader in the space, though concerns linger about market competition and past stock highs. The mix of hope and skepticism keeps the dialogue lively.
Note: This discussion summary was generated from an AI condensation of post data.
CRISPR Therapeutics Insider Trading Activity
CRISPR Therapeutics insiders have traded $CRSP stock on the open market 9 times in the past 6 months. Of those trades, 4 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $CRSP stock by insiders over the last 6 months:
- SIMEON GEORGE has made 3 purchases buying 989,812 shares for an estimated $51,499,918 and 0 sales.
- SAMARTH KULKARNI (Chief Executive Officer) has made 0 purchases and 3 sales selling 68,218 shares for an estimated $4,499,456.
- DOUGLAS A TRECO purchased 20,000 shares for an estimated $1,140,600
- NAIMISH PATEL (Chief Medical Officer) sold 3,932 shares for an estimated $141,316
- JAMES R. KASINGER (General Counsel and Secretary) sold 1,076 shares for an estimated $71,661
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CRISPR Therapeutics Hedge Fund Activity
We have seen 204 institutional investors add shares of CRISPR Therapeutics stock to their portfolio, and 193 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,452,819 shares (+132.1%) to their portfolio in Q2 2025, for an estimated $167,945,116
- ORBIS ALLAN GRAY LTD added 1,201,600 shares (+76.9%) to their portfolio in Q2 2025, for an estimated $58,445,824
- GEODE CAPITAL MANAGEMENT, LLC added 1,025,979 shares (+98.1%) to their portfolio in Q2 2025, for an estimated $49,903,618
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 988,061 shares (-50.6%) from their portfolio in Q2 2025, for an estimated $48,059,287
- STATE STREET CORP added 859,334 shares (+35.6%) to their portfolio in Q2 2025, for an estimated $41,798,005
- MORGAN STANLEY removed 788,602 shares (-60.7%) from their portfolio in Q2 2025, for an estimated $38,357,601
- UBS GROUP AG added 771,685 shares (+37.2%) to their portfolio in Q2 2025, for an estimated $37,534,758
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CRISPR Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $CRSP in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 10/17/2025
- Needham issued a "Buy" rating on 10/10/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/23/2025
- JP Morgan issued a "Overweight" rating on 09/18/2025
- Chardan Capital issued a "Buy" rating on 08/05/2025
- Piper Sandler issued a "Overweight" rating on 06/27/2025
- JMP Securities issued a "Market Outperform" rating on 06/27/2025
To track analyst ratings and price targets for CRISPR Therapeutics, check out Quiver Quantitative's $CRSP forecast page.
CRISPR Therapeutics Price Targets
Multiple analysts have issued price targets for $CRSP recently. We have seen 11 analysts offer price targets for $CRSP in the last 6 months, with a median target of $80.0.
Here are some recent targets:
- Geoff Meacham from B of A Securities set a target price of $93.0 on 10/17/2025
- Gil Blum from Needham set a target price of $81.0 on 10/10/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $80.0 on 09/23/2025
- Brian Cheng from JP Morgan set a target price of $70.0 on 09/18/2025
- Gena Wang from Barclays set a target price of $56.0 on 08/06/2025
- Luca Issi from RBC Capital set a target price of $42.0 on 08/05/2025
- Geulah Livshits from Chardan Capital set a target price of $82.0 on 08/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
